Navigation Links
Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
Date:1/8/2013

ROCHESTER, Minn. -- A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone, says lead researcher Keith Bible, M.D., Ph.D., a Mayo Clinic oncologist.

Anaplastic thyroid cancer is a rare but devastating form of thyroid cancer that typically strikes men and women in their 60s and 70s. It is very aggressive, with a median survival of only about 5 months from time of diagnosis. Only 20 percent of patients survive a year beyond diagnosis, and it has historically been found to be resistant to most therapies.

Pazopanib, a kinase-inhibitor that interferes with the growth of cancer cells, is already approved by the Food and Drug Administration (FDA) to treat renal cancer tumors. Paclitaxel is an FDA-approved chemotherapy drug that disrupts the machinery involved in cell division.

Researchers studied anaplastic thyroid cancer cells and tumors in cell culture and in animal models. Human ATC cells were readily killed, and ATC tumors implanted into mice were 50 percent smaller when treated with the combination in comparison to the response to treatment with either drug alone. Pilot therapy of one patient with metastatic anaplastic thyroid cancer using the combination also resulted in marked tumor shrinkage lasting over six months. "This was a highly unexpected finding for this type of aggressive tumor, which often can double in size in a matter of days," Dr. Bible says.

In previous studies, pazopanib alone was found not effective in the treatment of anaplastic thyroid cancer. Paclitaxel was added to address the aggressiveness of anaplastic thyroid cancer tumors and bolster anti-cancer effects. The team investigated how the two drugs might complement each other.

Monitoring cancer cells multiply in time-lapse video under a microscope, researchers noted that the drug combination resulted in abnormal cell division and an increase in ATC cell death. Although pazopanib had not been known to specifically affect cell division, researchers speculated that the drug might have another unrecognized molecular target within cancer cells.

"We ended up learning that pazopanib also happens to inhibit a protein involved in cell division known as aurora A; this property seems to be involved in producing enhanced effects when pazopanib is combined with paclitaxel," Dr. Bible says. "This finding suggests that the combination may also be useful in treating other cancers, such as breast cancer, in which aurora A is sometimes found to be present in elevated amounts, as it is in ATC," Dr. Bible says.

The results also prompted an ongoing randomized multicenter clinical trial, led by Mayo Clinic and Memorial Sloan-Kettering Cancer Center and administered through the Radiation Therapy Oncology Group, testing the two-drug combination when added to radiation therapy in the initial treatment of patients with anaplastic thyroid cancer.

"This important next step is designed to determine whether the combination of drugs will improve ATC patient survival compared to paclitaxel alone," Dr. Bible says.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
2. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
3. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
4. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
5. Mayo Clinic: Common blood pressure drug linked to severe GI problems
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
8. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
9. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
10. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
11. Immunotherapy for elderly cancer patients finds new promise in drug combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth ... pain whenever they brush their teeth. Sadly, most dental hygiene products in the market ... and teeth. For these people, continuing their daily oral care routine to keep their ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... Friday, January ... area of the game room, increasing the size of the location to 90,000 square ... an 8-hole mini golf course that takes customers on an educational tour of the ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... MyGenetx, a ... of Communications, and Sales Administration Specialist, Mary Taylor Smith, RD, LD, will serve on ... after serving one year as a board member and one year as Vice President. ...
(Date:1/13/2017)... Boulder, CO (PRWEB) , ... January 13, 2017 , ... ... Congress, a growing alliance of deans of colleges and schools of education across the ... public schools. , In a Declaration of Principles released today, 175 deans sounded the ...
(Date:1/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... a way to peace, health and eternal joy. Yisrayl says he has been accused of ... adds that false accusations and persecution are nothing new in his world and says it ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... ... has announced the addition of the "Immunotherapy Drugs Market by Type ... their offering. The global immunotherapy drugs market is projected ... 2016, growing at a CAGR of 13.5% during the forecast period of ... fewer side effects, quicker drug approval processes, and high prevalence rate of ...
(Date:1/12/2017)... , Jan. 12, 2017 Probiotics ... benefits when consumed, which facilitate digestion, gastrointestinal movement ... There have been 500 million probiotics consumers ... realize 15% in some European countries. The probiotics ... the developed countries. In developed countries, probiotic ...
(Date:1/12/2017)... , Jan. 12, 2017  Harrington Discovery Institute ... and the Alzheimer,s Drug Discovery Foundation ... of innovative research efforts for Alzheimer,s disease. Together, ... a new award program for academic researchers. By ... Discovery Institute and the ADDF will advance Alzheimer,s ...
Breaking Medicine Technology: